Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Advanced Pancreatic Cancer 1

Interventions

Oxaliplatin 151Fluorouracil 136Gemcitabine 117Bevacizumab 114Specimen Handling 104Leucovorin 104Capecitabine 95pembrolizumab 90Magnetic Resonance Spectroscopy 82Nivolumab 79Cisplatin 79Irinotecan 69durvalumab 63Cetuximab 61Paclitaxel 60Biopsy 60130-nm albumin-bound paclitaxel 58Radiotherapy 46atezolizumab 44Albumin-Bound Paclitaxel 37Taxes 36Carboplatin 36Folfox protocol 34Drug Therapy 32lenvatinib 29dehydroftorafur 29Cyclophosphamide 28tislelizumab 27sintilimab 27Radiation 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
penpulimab × Gastrointestinal × 90 days × Clear all
NCT06821503 2026-03-10

Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Recruiting
72 enrolled
Gastrointestinal

Advanced Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡